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Science Goes to Work 
As president and co-founder of Essen BioScience, Kirk  
Schroeder ’84 creates high-tech innovations and American jobs. 
Story by SALLY 
POBOJEWSKI 
Kirk Schroeder ’84 is more 
comfortable in jeans and T-shirt 
than a suit and tie. He’d rather 
partner up for a game of euchre 
with colleagues at lunch than 
network with other business 
executives. He drives a 1995 
Dodge Ram pickup, not a Lexus. 
And he’s much more interested in 
talking about his company than in 
talking about himself. 
He may not fit the stereotype, but 
Schroeder, 49, is an all-American 
business success story as president 
and co-founder of Essen 
BioScience, a privately owned 
company with 66 employees. 
Based in Ann Arbor, Mich., Essen develops and manufactures high-tech research instruments 
and provides research services for clients in the global pharmaceutical and biotechnology 
industries. To date, the company’s inventions have accounted for nearly $1 billion in worldwide 
sales. 
Schroeder and his business partner, Brad Neagle, built Essen from the ground up the old-
fashioned way. No venture capital funding. No leveraged buyouts. Just innovative ideas, sweat 
equity and hard work. 
At a time when most U.S. businesses are outsourcing to reduce operating costs, Essen’s products 
are still made in America, and Schroeder intends to keep it that way. 
“We do everything possible ourselves,” says Schroeder, sitting in his small office with 
minimalist décor — bare walls, one small desk lamp and a computer — at Essen’s newly 
renovated, 25,000-square-foot headquarters. “We do our own R&D, we write the software, and 
we use a local machine shop to make most of the component parts.” 
 
Schroeder monitors progress in a lab at Essen’s Ann 
Arbor headquarters. (Photo by Leisa Thompson) 
Creating local jobs and manufacturing products in the U.S.A. is a point of pride for Schroeder. 
He also believes that controlling the entire process gives Essen a competitive advantage. “Every 
time we’ve given up control,” he says, “it’s proven to be a mistake.” 
From garage to breakthrough 
Schroeder’s work ethic and independent streak 
have roots in his rural upbringing on his 
family’s farm near Watseka, Ill. He arrived at 
Illinois Wesleyan in 1980, selected physics as 
his major and studied with professors Gary 
Kessler, Lew Detweiller and Ray Wilson. As a 
sophomore, he was awarded IWU’s Scott 
Anderson Scholarship for Physics. 
Schroeder says his physics major taught him 
how to solve problems and gave him confidence 
that he could understand any field of science. In 
addition, the liberal-arts focus of his Wesleyan 
education — including classes in philosophy, 
writing and religion — helped him succeed in 
business. 
“My job mostly involves negotiating, hiring, forming collaborations and planning,” says 
Schroeder. “The liberal arts education certainly helped with the communication and writing 
skills I use every day.” 
After graduating from IWU, Schroeder enrolled in graduate school at the University of Illinois to 
study applied optics. After receiving his master’s in electrical engineering in 1986, he moved to 
Ann Arbor to start his first job at the nonprofit Environmental Research Institute of Michigan 
(ERIM). Schroeder worked as a research engineer in the optical science laboratory that did 
contract work for the U.S. Department of Defense. 
“It was during the Reagan ‘Star Wars’ era, so we got to work with expensive lasers, optical 
instruments and solid-state sensors,” he says. “That technology field was really blossoming at the 
time.” 
At ERIM, Schroeder first met Neagle, a shy, quiet University of Michigan engineering student 
who worked down the hall. The two became close friends. 
“Kirk was a weight lifter who worked out for three hours every day and ate tuna straight out of 
the can,” recalls Neagle, 47. “He was pretty intense and never did anything halfway.” 
Through “a friend of a friend,” Schroeder and Neagle learned of a new project at the 
pharmaceutical firm Upjohn that would change their lives. 
 
Schroeder, left, and business parter Brad 
Neagle work out a manufacturing schedule 
for their newest product, IncuCyte. (Photo 
by Leisa Thompson) 
At Upjohn, researcher Vincent Groppi had developed a lab test to measure membrane potential, 
which is the voltage difference between the inside and outside of a cellular membrane. 
Membrane potential governs a cell’s ability to send and receive signals in the form of electrically 
charged particles called ions. 
Upjohn saw potential for using this process to test the effects of hundreds of thousands of 
experimental drug compounds on cells. Today, this type of testing — called cell-based, high-
throughput screening — is a staple of preclinical, drug-discovery research. But there was a 
hurdle to make the test a reality. It required a new kind of scientific instrument: one that 
incorporated optics, fluidics, automation and integrated software. 
With their experience in lasers and optics, Schroeder and Neagle believed they could build such 
an instrument. They were engineers, not life scientists, but Groppi offered to teach them the 
biology. Schroeder and Neagle convinced ERIM to provide some funding and Upjohn agreed to 
buy the prototype, if it worked. 
After a few false starts, Neagle and Schroeder built a prototype device that could measure 
electrochemical activity of 96 living cells simultaneously. They called it FLIPR (short for 
Fluorescent Imaging Plate Reader). Upjohn’s researchers were so excited by FLIPR’s potential 
that Schroeder thought other companies might want one, too. Cold-calling pharmaceutical 
scientists at other firms doing similar research, he learned he was correct. 
Schroeder and Neagle began making FLIPRs in a local garage. Each unit required well over 
$100,000 in parts and took months to build. With so much time and money invested, they did not 
trust shipping the product so instead drove rental vans to deliver FLIPRs to customers 
themselves. 
“All the money we had in the world was in that van,” Schroeder says. “We drove one to New 
Jersey and parked it outside the gates at Merck waiting to deliver first thing in the morning. It 
was just down the road from Rahway State Prison, not in the best neighborhood. When we woke 
up that morning, one of our tires was missing.” 
By the spring of 1996, the pair had orders for about 10 FLIPRs. Although both had left their jobs 
at ERIM to meet the demand, they struggled to keep up. So they accepted an offer from a West 
Coast company, Molecular Devices Corporation (MDC). MDC purchased rights to the FLIPR 
technology, hired Schroeder and Neagle and moved the entire operation to its Sunnyvale, Calif., 
headquarters. 
At first, being part of the corporate world was a positive experience, says Schroeder. He and 
Neagle now had time to develop new applications for FLIPR — including a system that could 
detect calcium ions within a cell, a signal that key receptor molecules in the cell’s membrane had 
been activated. But after a few years, they began to chafe at the restrictions of working for a 
large corporation. Neagle had two young daughters and wanted to raise his family in Ann Arbor. 
So, in 1999, they left Molecular Devices and moved back to Michigan to start a new company, 
Essen Instruments. 
All-American business model 
As Essen grew, a division of 
labor developed between the 
two partners. Neagle handled 
the engineering, while 
Schroeder focused on the 
biology and business 
management. 
“My skills are in solving 
engineering problems,” says 
Neagle. “Kirk has those skills, 
too, but his strength is in 
understanding the biology. He 
can take any problem and figure 
out how to solve it. He’s 
constantly training and learning 
new things.” 
“I’m more of a risk-taker and 
Brad’s a little more conservative 
in this respect,” Schroeder says. “From a business-decision point of view, this is a good thing. I 
always think things are going to be easier and more doable than they really are, and Brad’s 
influence helps insure we don’t get too far ahead of ourselves.” 
First on Essen’s drawing board was a product called IonWorks. It was designed to automate a 
common lab procedure called a patch-clamp test that’s used in drug-discovery research to 
measure the electrical activity of individual cells. Instead of taking 15 to 20 minutes to conduct a 
patch-clamp test on one cell, Essen’s IonWorks prototype could test 384 cells simultaneously. 
Patent complications and the fact that Schroeder and Neagle didn’t have the money to self-fund 
its entire development led to their decision to license the IonWorks technology to Molecular 
Devices. IonWorks turned out to be a second blockbuster product for the California firm. 
Royalties from IonWorks sales provided some much-needed financial security and helped Essen 
grow, but Schroeder still regrets having to give up the product that Essen had developed and 
nurtured. 
Schroeder plans to retain Essen ownership of its newest product line, IncuCyte, a system that 
captures microscopic images of living cells as they grow inside an incubator. IncuCyte gives 
researchers the ability to monitor cells continuously, leading to better understanding of how cells 
respond to changes inside the body. 
“The one thing Brad and I have always done differently than a lot of instrumentation companies 
in our area is that we understand and perform the biology in-house,” Schroeder says. “We build 
better tools and assays, because we actually use the tools that we build in our service business.” 
 
Schroeder observes as Essen application scientists test a 
new cell culture insert, measuring cell migration. (Photo 
by Leisa Thompson) 
Emphasizing customer service and maintaining “lifetime bonds” with customers are part of 
Essen’s success, according to Schroeder. So is bringing researchers who are creative and highly 
motivated. Many of the scientists he and Neagle worked with prior to launching Essen are now 
employed by the company or serve on its board of directors. 
In recent years, Schroeder has seen 
fundamental changes sweep through the 
pharmaceutical industry. Many of his original 
customers — major corporations like Merck, 
Astra-Zeneca and Pfizer — have sold or 
downsized most of their drug-discovery 
research facilities in favor of cheaper labor 
overseas or alternative business models. New, 
smaller pharmaceutical and biotechnology 
companies are being created to fill the void, 
but they can’t always afford or have the 
process demands of a half-million-dollar 
research instrument. 
So Essen now has a new business model and a new name: Essen BioScience. Instead of focusing 
solely on developing, manufacturing and selling research instruments, Schroeder says the 
company also performs drug-screening assays on a contract basis for small, start-up firms. 
“It’s another way for us to get access to customers,” he says. “We’re also developing 
collaborative drug-discovery projects with some of our customers.” 
Schroeder doesn’t have much good to say about the current state of American business, 
especially domestic manufacturing. He blames an emphasis on short-term profits for the 
recession that has closed factories across the country and sent millions of Americans to 
unemployment lines. 
“To keep and grow jobs, you can’t make business decisions based on what’s good in the next 
three to nine months,” he says. “You have to invest in the future. Right now, we’re reinvesting 
just about everything we make in this company. If we were a public company and I had investors 
breathing down my neck about this quarter’s earnings, we couldn’t do that.” 
Proof that Essen’s business model is working: It is in its seventh consecutive year of organic 
revenue growth and recently opened offices in England and Japan for sales, service and support 
of its U.S.-made products in European and Asian markets. 
Schroeder has a two-word solution to America’s economic crisis: “build stuff,” and build it in 
this country. “When manufacturing goes overseas, R&D soon follows along with the knowledge 
base necessary to innovate. In my opinion, if you want to generate jobs, you need to design and 
build things.” 
 
 Essen BioScience’s newly renovated, 25,000-
square-foot headquarters. 
Despite his strong opinions on domestic manufacturing, Schroeder likes to let the products and 
services provided by Essen’s Michigan employees do most of the talking. 
“I’d prefer to fly beneath the radar,” he says, looking eager to get back to the busy job of putting 
business and science to work. 
 
